ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

calcipotriene

Also written as “LEO 90100”, “MC2-01 cream” and “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”.

Its studies are mostly in Psoriasis · Alopecia Areata, led by 10 companies.

Drug pageCalcipotriene: every studyMany companies study it; this page follows only the 37 they lead. All 70 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 15, 200537 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
LEO Pharmaits history only220 open or runningphase 4since Sep 15, 2005Sep 15, 2005none ahead
MC2 Therapeuticsits history only50 open or runningphase 3since Oct 9, 2017Oct 9, 2017none ahead
Almirall20 open or runningphase 3since Nov 11, 2015Nov 11, 2015none ahead
Mayne Pharma International Ptyits history only20 open or runningphase 1since Mar 15, 2012Mar 15, 2012none ahead
Abbottits history only10 open or runningphase 3since Dec 12, 2007Dec 12, 2007none ahead
Egymedicalpediaits history only10 open or runningno phasesince Jun 23, 2023Jun 23, 2023none ahead
GlaxoSmithKlineits history only10 open or runningphase 3since Jun 6, 2010Jun 6, 2010none ahead
Glenmark Pharmaceuticals Ltd. Indiaits history only10 open or runningphase 3since Nov 1, 2017Nov 1, 2017none ahead
Huadong Medicineits history only10 open or runningphase 3since Dec 11, 2025Dec 11, 2025none ahead
Tolmarits history only10 open or runningphase 1since Apr 6, 2017Apr 6, 2017none ahead

Also a collaborator on its studies: Bioskin.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Almirall only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 11, 2015First study: phase 3 study in Nail PsoriasisFirst studyNCT02606760 · 378 enrolled · Bulgaria, Czechia, Germany and more
  2. Mar 9, 2017Phase 3 study in Nail PsoriasisNCT03079973 · United States

TargetBeta

VDR →read by rule
“Vitamin D receptor agonist”ChEMBL 37, by rule

Other programs on VDR

ProgramCompanyFurthest phaseStudies
Modified-release Calcifediol CapsuleruleOPKO Healthphase 310

Studies

All 2 Almirall leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03079973Nail Psoriasis · United States3WithdrawnJul 20180
NCT02606760Nail Psoriasis · Bulgaria, Czechia, Germany and more3CompletedFeb 8, 2017378

How it is read

Names in the registry

  • “LEO 90100”, 7 entries
  • “MC2-01 cream”, 4 entries
  • “Calcipotriol plus betamethasone dipropionate (LEO80185 gel)”, 3 entries
  • “Calcipotriol plus hydrocortisone (LEO 80190)”, 2 entries
  • “MC2-01 Cream”, 2 entries

Codes read as this program: P3073.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.